Investigational Drug Information for Trodusquemine
What is the development status for investigational drug Trodusquemine?
Trodusquemine is an investigational drug.
There have been 4 clinical trials for Trodusquemine.
The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2016.
The most common disease conditions in clinical trials are Diabetes Mellitus, Breast Neoplasms, and Overweight. The leading clinical trial sponsors are Genaera Corporation, DepYmed Inc., and Northwell Health.
Summary for Trodusquemine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 585 |
| WIPO Patent Applications | 178 |
| Japanese Patent Applications | 22 |
| Clinical Trial Progress | Phase 1 (2016-04-01) |
| Vendors | 29 |
Recent Clinical Trials for Trodusquemine
| Title | Sponsor | Phase |
|---|---|---|
| Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer | DepYmed Inc. | Phase 1 |
| Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer | Northwell Health | Phase 1 |
| An Ascending Multi-Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers | Genaera Corporation | Phase 1 |
Clinical Trial Summary for Trodusquemine
Top disease conditions for Trodusquemine
Top clinical trial sponsors for Trodusquemine
US Patents for Trodusquemine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Trodusquemine Development Update and Market Projection
Trodusquemine, also known as MSI-1436, is an investigational aminosterol and protein tyrosine phosphatase 1B inhibitor. Its clinical development has not produced an approved medicine, a registrational obesity program, or a commercial product. Public development activity appears to have stalled after early-stage studies in obesity, type 2 diabetes, cancer, and other indications.
The near-term commercial value of trodusquemine is therefore negligible. Its long-term value depends on whether a sponsor can restart development, establish a differentiated clinical profile against GLP-1 and GIP therapies, and solve its injectable-delivery and tolerability constraints.
What is trodusquemine and how does it work?
Trodusquemine is a synthetic aminosterol derived from shark immune-system compounds. Its primary pharmacologic target is protein tyrosine phosphatase 1B, or PTP1B, an intracellular negative regulator of insulin and leptin signaling.
The intended effects are:
- Increased insulin-receptor signaling
- Improved leptin sensitivity
- Reduced food intake
- Weight loss
- Potential improvement in glucose metabolism
PTP1B inhibition has long been viewed as a potential strategy for obesity and type 2 diabetes. Trodusquemine differs from GLP-1 receptor agonists because it is intended to act through intracellular signaling rather than gut-derived incretin pathways.
Preclinical work reported effects on body weight, insulin sensitivity, and leptin signaling in animal models. Translation into a competitive human efficacy profile has not been demonstrated in publicly available clinical data. [1]
What was the original development rationale?
The development rationale was strongest in obesity associated with leptin resistance and insulin resistance. The mechanism could theoretically address two metabolic pathways at the same time. Trodusquemine also generated interest in oncology because PTP1B signaling has links to growth-factor pathways and tumor biology.
The clinical risk was the need to demonstrate durable weight loss and acceptable safety with an injectable small molecule in a market increasingly dominated by once-weekly or less-frequent incretin therapies.
What is the current development status of trodusquemine?
Trodusquemine does not have FDA approval and is not marketed in the United States or major international markets. It has not reached a public Phase 3 program for obesity or diabetes.
Publicly identifiable development has included early-phase studies evaluating:
| Area | Development objective | Public status |
|---|---|---|
| Obesity | Safety, tolerability, pharmacokinetics, and weight-loss signal | Early-stage development; no public registrational continuation |
| Type 2 diabetes | Glucose and insulin-related effects | Early-stage development; no approved indication |
| Oncology | Safety and antitumor activity in advanced disease | Exploratory clinical development; no established efficacy |
| Other metabolic uses | Mechanistic or translational assessment | No confirmed commercial program |
ClinicalTrials.gov records identify early clinical investigations of MSI-1436 and trodusquemine, but the public record does not show a completed pivotal program supporting an FDA filing. [2]
The candidate’s development status should be classified as inactive or commercially dormant rather than late-stage. That classification may change only if a sponsor announces a new clinical-development agreement, an investigational new drug restart, or a new Phase 1 study.
When could trodusquemine lose exclusivity?
Trodusquemine has no marketed-product exclusivity period because it has not received FDA approval. It therefore has no Hatch-Waxman approval date, five-year new chemical entity exclusivity period, three-year clinical-investigation exclusivity period, or Orange Book-listed expiration date.
The relevant intellectual-property risk comes from older composition-of-matter, use, and formulation filings. Because the compound was studied clinically many years ago, early patent families may already have expired or may be approaching the end of their enforceable terms. Patent-term adjustment, patent-term extension, terminal disclaimers, continuations, and jurisdiction-specific prosecution could alter individual expiration dates.
A precise live patent-expiration analysis cannot be inferred from the drug name alone. The public regulatory record does not identify a current Orange Book patent estate for trodusquemine. The practical conclusion is that a new sponsor would likely need to rely on:
- New formulation patents
- New dosing regimens
- Combination-treatment patents
- Patient-selection claims
- Manufacturing or crystalline-form claims
- New clinical data supporting method-of-use protection
What patents protect trodusquemine?
The historic patent position was associated with PTP1B inhibition, aminosterol chemistry, therapeutic uses, and related pharmaceutical compositions. Public patent databases contain patent families covering aminosterol compounds and their use in metabolic or proliferative disorders.
The strategic strength of the historic estate is limited by age. Earlier composition patents are normally the most valuable protection for a small molecule, but those patents lose value as their filing dates recede. Later method-of-use patents can protect a narrow commercial label but are less effective against off-label use or alternative treatment protocols.
No publicly confirmed Orange Book listing protects an approved trodusquemine product. No approved product means no listed patents under FDA’s Orange Book framework. [3]
What formulations are protected by trodusquemine patents?
Trodusquemine development has involved injectable administration. Formulation protection would be important because the compound is not positioned as an oral obesity medicine.
Potential formulation claims could address:
- Aqueous injectable solutions
- Concentration and pH ranges
- Stabilizers and excipients
- Container-closure systems
- Sterile manufacturing processes
- Dosing schedules that reduce injection-site reactions
No marketed formulation has generated an Orange Book patent listing. Any current formulation advantage would need to be established through newly filed patent applications and supported by clinical or manufacturing data.
Has trodusquemine faced Paragraph IV challenges?
No public Paragraph IV litigation is associated with an approved trodusquemine product. Paragraph IV certifications apply to abbreviated new drug applications referencing an approved product with Orange Book-listed patents. Trodusquemine has no approved reference product and no identified Orange Book patent listing.
A future generic challenge would therefore require a sponsor first to obtain approval and establish a listed product. If development restarts under a new formulation or indication, the timing of any Paragraph IV risk would depend on the approved label, listed patents, and generic filing strategy.
What is the FDA regulatory status of trodusquemine?
The FDA has not approved trodusquemine for obesity, diabetes, cancer, or any other indication. It is not a biologic, so biosimilar pathways do not apply. Any future development would proceed through the conventional small-molecule drug pathway:
- Preclinical and chemistry, manufacturing, and controls work
- Investigational new drug application
- Phase 1 safety and pharmacokinetic studies
- Phase 2 dose-ranging and proof-of-concept studies
- Phase 3 confirmatory trials
- New drug application review
Prior early-stage exposure would not eliminate the need for a modern development package. A new sponsor would likely need current toxicology, validated manufacturing controls, updated pharmacokinetics, and a clinical plan reflecting the present obesity-treatment standard.
Which companies have developed or controlled trodusquemine?
Trodusquemine was historically associated with Genaera Corp. and its predecessor development activities. Later development references have used the name Trodus Therapeutics. The public record does not show a current large-pharmaceutical sponsor operating a late-stage trodusquemine program.
| Organization | Apparent role | Current commercial implication |
|---|---|---|
| Genaera and predecessor entities | Historical development and intellectual-property association | Legacy asset position |
| Trodus Therapeutics | Later development and licensing association | No confirmed marketed product |
| Large pharmaceutical companies | No confirmed active late-stage owner | No validated commercialization partner |
The absence of a visible large-pharmaceutical sponsor is material. Obesity assets with credible late-stage efficacy are attracting substantial licensing and acquisition interest. Trodusquemine has not generated comparable disclosed transaction activity.
What patent litigation affects trodusquemine?
No material public patent litigation involving an approved trodusquemine product is identified. The absence of litigation is consistent with the candidate’s noncommercial status.
Potential future disputes would most likely concern:
- Ownership of legacy compound patents
- Inventorship and licensing rights
- New injectable formulations
- Dosing regimens
- Combination use with GLP-1 receptor agonists
- Patent scope for obesity or metabolic indications
There is no current litigation-based barrier to generic entry because there is no approved product to challenge.
How does trodusquemine compare with semaglutide and tirzepatide?
Trodusquemine is commercially disadvantaged against semaglutide and tirzepatide because it lacks approved efficacy, cardiovascular-outcomes data, manufacturing scale, and reimbursement precedent.
| Attribute | Trodusquemine | Semaglutide | Tirzepatide |
|---|---|---|---|
| Modality | Small-molecule aminosterol | Peptide GLP-1 agonist | Peptide GIP/GLP-1 agonist |
| Administration | Investigational injectable | Injectable and oral forms, depending on product | Injectable; oral development has also been pursued |
| FDA obesity approval | No | Yes, under Wegovy | Yes, under Zepbound |
| Late-stage efficacy package | No public pivotal package | Established | Established |
| Cardiometabolic evidence | Limited early-stage evidence | Extensive | Expanding |
| Commercial access | None | Broad and growing | Broad and growing |
| Patent position | Historic and potentially aged | Extensive active estate | Extensive active estate |
The competitive burden is high. A restarted trodusquemine program would need either materially better tolerability, a distinct mechanism with additive efficacy, a lower-cost manufacturing profile, or utility in patients who do not respond adequately to incretin therapy.
What is the market projection for trodusquemine?
A conventional revenue forecast is not supportable because trodusquemine has no active registrational program, approval probability, launch date, or validated dose. The appropriate projection is scenario-based.
| Scenario | Development assumption | Commercial outlook |
|---|---|---|
| Base case | No meaningful clinical restart | Zero product revenue |
| Restart case | New sponsor conducts Phase 1 and Phase 2 studies | Limited value during development; partnering value depends on proof of concept |
| Positive case | Strong obesity efficacy and acceptable injectable tolerability | Potential niche or combination product |
| Breakout case | Differentiated efficacy, safety, and manufacturing economics | Possible specialty obesity franchise, but low probability |
The underlying obesity market is large, with global anti-obesity drug sales expected to grow substantially through the end of the decade. That market size does not translate directly into trodusquemine value. Market access is controlled by clinical efficacy, supply capacity, payer coverage, and long-term safety.
A practical probability-adjusted view is:
- Near-term revenue through 2027: effectively zero unless clinical development restarts
- Near-term licensing value: low, given the absence of public late-stage data
- Long-term unadjusted opportunity: potentially meaningful in obesity or combination therapy
- Long-term risk-adjusted value: low until human efficacy and safety are re-established
A successful restart could target a niche rather than direct replacement of semaglutide or tirzepatide. Potential niches include patients with inadequate incretin response, combination therapy, or metabolic disease where leptin and insulin signaling provide a clinically meaningful advantage.
What generic launch risks exist?
There is no current generic-launch risk because no approved reference product exists. If trodusquemine were approved in the future, launch risk would depend on the strength of new patents rather than legacy patents alone.
The principal risks would be:
- Weak or expired composition-of-matter protection
- Narrow method-of-use claims
- Injectable formulation workarounds
- Off-label use outside the approved label
- Limited protection for the active pharmaceutical ingredient
- Manufacturing competition from contract drug manufacturers
A new sponsor would need to build a patent estate around the commercial product, not rely solely on historical MSI-1436 filings.
Key Takeaways
- Trodusquemine, or MSI-1436, is an investigational PTP1B inhibitor and aminosterol.
- It has no FDA approval, no marketed product, and no Orange Book listing.
- Public development has remained at an early clinical stage, with no confirmed Phase 3 obesity program.
- No Paragraph IV litigation or approved-product patent dispute is identified.
- The historic patent estate is likely weakened by age and requires jurisdiction-specific review.
- Biosimilar risk does not apply because trodusquemine is a small molecule.
- The near-term revenue projection is effectively zero without a clinical restart.
- Any future value would depend on differentiated efficacy against semaglutide, tirzepatide, and other incretin therapies.
- New formulation, dosing, combination, and patient-selection patents would likely be central to a restart strategy.
FAQs About Trodusquemine
Is trodusquemine approved for weight loss?
No. The FDA has not approved trodusquemine for weight loss, obesity, diabetes, or any other indication.
Is trodusquemine a GLP-1 drug?
No. Trodusquemine is a PTP1B inhibitor and does not belong to the GLP-1 receptor agonist class.
Can trodusquemine be prescribed today?
No approved commercial product is available for routine prescription. Its clinical use is limited to authorized research settings, if an active study is available.
Does trodusquemine have biosimilar competition?
No. Trodusquemine is a small molecule, so any future competition would generally involve generic-drug pathways rather than biosimilar regulation.
Could trodusquemine be developed as a combination with semaglutide?
Potentially, but that strategy would require new preclinical and clinical evidence showing additive or synergistic benefit, acceptable safety, and a commercially defensible dosing regimen.
References
-
Stanford University School of Medicine. (2014). PTP1B inhibition and metabolic disease research. Stanford Medicine research publications.
-
U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov search results for trodusquemine and MSI-1436. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Public Search. https://ppubs.uspto.gov/ and https://patentcenter.uspto.gov/
More… ↓
